| |
|
|
|
|
| Slide Lecture Programs |
| 2006 Core Curriculum |
| Contemporary Management of Myocardial Ischemia |
May 17, 2006
|
| V: |
New Therapeutic Options for Chronic Stable Angina |
Slide 69 |
|
Download PowerPoint
|
Ranolazine: Drug interactions
- Ranolazine is primarily metabolized by CYP3A. Potent or moderately potent inhibitors of this enzyme will increase ranolazine plasma levels and QTc. Their concomitant administration should be avoided.
- Less potent CYP3A inhibitors such as simvastatin and cimetidine did not increase the exposure to ranolazine in healthy volunteers.
- Plasma concentrations are not significantly altered by concomitant digoxin at 0.125 mg qd.
|
|
|
Resources
